The nation’s preeminent cancer hospitals are charging commercial health insurers anywhere from double to seven times their costs of acquiring cancer drugs, a new study shows.
Most top cancer institutions also are keeping their drug prices secret in direct violation of federal law, potentially exposing themselves to fines.
The findings reinforce how cancer care, especially the drugs, generates significant revenue for hospitals, and how markups on drugs potentially put insured cancer patients in financially perilous situations.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
